文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

促肾上腺皮质激素刺激后的类固醇谱预测脓毒症休克发生与死亡:来自HYPRESS研究

Corticotropin-stimulated steroid profiles to predict shock development and mortality in sepsis: From the HYPRESS study.
PubMed 文献 · Crit Care · 2022-11-07
一句话结论在未休克脓毒症患者中,促肾上腺皮质激素刺激后皮质醇与皮质酮比值>32.2可预测院内死亡(AUC 0.8)。

该研究为HYPRESS随机双盲试验的探索性数据分析,纳入未休克的成年脓毒症患者180例及健康志愿者20例,在随机化前进行促肾上腺皮质激素刺激试验,用LC-MS/MS检测皮质醇及糖皮质激素、盐皮质激素前体。结果显示脓毒症患者11-脱氧皮质酮和11-脱氧皮质醇水平较健康人升高,刺激后皮质醇反应低于正常者占12%、皮质酮反应低于正常者占50%。在安慰剂组(n=90)中,刺激后皮质醇与皮质酮比值>32.2预测院内死亡(AUC 0.8,CI 0.70-0.88;敏感性83%,特异性78%),该比值也预测休克发生风险和90天死亡。作者认为脓毒症中盐皮质激素合成受损比糖皮质激素更常见。

要点

  • 在未休克的脓毒症患者中,促肾上腺皮质激素刺激后皮质醇与皮质酮比值>32.2预测院内死亡,AUC 0.8(CI 0.70-0.88),敏感性83%,特异性78%(安慰剂组n=90)。
  • 该比值同时预测休克发生风险和90天死亡。
  • 脓毒症患者促肾上腺皮质激素刺激后皮质醇反应低于正常者占12%,皮质酮反应低于正常者占50%。
  • 与健康志愿者相比,脓毒症患者11-脱氧皮质酮和11-脱氧皮质醇水平升高,提示糖皮质激素和盐皮质激素通路均激活。

适用人群与场景

  • 成人脓毒症患者,未处于休克状态,来自HYPRESS随机双盲试验人群。
  • 健康志愿者20例用于确定参考范围。

诊断标准与关键阈值

  • 促肾上腺皮质激素刺激后皮质醇与皮质酮比值>32.2用于预测院内死亡(AUC 0.8,CI 0.70-0.88;敏感性83%,特异性78%),基于安慰剂组90例患者。

研究设计与关键结果

  • 研究类型:双盲随机试验(HYPRESS)的探索性数据分析;纳入180例脓毒症患者和20名健康志愿者。
  • 与健康受试者相比,脓毒症患者11-脱氧皮质酮和11-脱氧皮质醇水平升高,符合糖皮质激素和盐皮质激素通路激活。
  • 促肾上腺皮质激素刺激后,脓毒症患者中皮质醇反应低于正常者占12%,皮质酮反应低于正常者占50%。
  • 在安慰剂组(n=90)中,促肾上腺皮质激素刺激后皮质醇与皮质酮比值>32.2预测院内死亡:AUC 0.8(CI 0.70-0.88),敏感性83%,特异性78%。
  • 该比值也预测休克发生风险和90天死亡。

证据类型、等级与局限

  • 证据类型:双盲随机试验(HYPRESS)的探索性数据分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在脓毒症中盐皮质激素合成受损比糖皮质激素合成受损更常见。
  • 作者认为,促肾上腺皮质激素刺激后皮质醇与皮质酮比值可预测院内死亡风险。

指南或共识出处

  • HYPRESS(HYdrocortisone for PRevention of Septic Shock)试验,临床试验注册号NCT00670254,注册日期2008年5月1日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: Steroid profiles in combination with a corticotropin stimulation test provide information about steroidogenesis and its functional reserves in critically ill patients.

OBJECTIVES: We investigated whether steroid profiles before and after corticotropin stimulation can predict the risk of in-hospital death in sepsis.

METHODS: An exploratory data analysis of a double blind, randomized trial in sepsis (HYPRESS [HYdrocortisone for PRevention of Septic Shock]) was performed. The trial included adult patients with sepsis who were not in shock and were randomly assigned to placebo or hydrocortisone treatment. Corticotropin tests were performed in patients prior to randomization and in healthy subjects. Cortisol and precursors of glucocorticoids (17-OH-progesterone, 11-desoxycortisol) and mineralocorticoids (11-desoxycorticosterone, corticosterone) were analyzed using the multi-analyte stable isotope dilution method (LC-MS/MS). Measurement results from healthy subjects were used to determine reference ranges, and those from placebo patients to predict in-hospital mortality.

MEASUREMENTS AND MAIN RESULTS: Corticotropin tests from 180 patients and 20 volunteers were included. Compared to healthy subjects, patients with sepsis had elevated levels of 11-desoxycorticosterone and 11-desoxycortisol, consistent with activation of both glucocorticoid and mineralocorticoid pathways. After stimulation with corticotropin, the cortisol response was subnormal in 12% and the corticosterone response in 50% of sepsis patients. In placebo patients (n = 90), a corticotropin-stimulated cortisol-to-corticosterone ratio > 32.2 predicted in-hospital mortality (AUC 0.8 CI 0.70-0.88; sensitivity 83%; and specificity 78%). This ratio also predicted risk of shock development and 90-day mortality.

CONCLUSIONS: In this exploratory analysis, we found that in sepsis mineralocorticoid steroidogenesis was more frequently impaired than glucocorticoid steroidogenesis. The corticotropin-stimulated cortisol-to-corticosterone ratio predicts the risk of in-hospital death. Trial registration Clinical trial registered with www.

CLINICALTRIALS: gov Identifier: NCT00670254. Registered 1 May 2008, https://clinicaltrials.gov/ct2/show/NCT00670254 .

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Briegel J, Möhnle P, Keh D, et al. Corticotropin-stimulated steroid profiles to predict shock development and mortality in sepsis: From the HYPRESS study. Crit Care. 2022. PMID: 36345013. doi:10.1186/s13054-022-04224-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。